MYFEMBREE
Total Payments
$29.4M
Transactions
108,462
Doctors
20,490
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12.8M | 22,255 | 8,117 |
| 2023 | $10.7M | 35,064 | 11,274 |
| 2022 | $4.4M | 34,996 | 11,126 |
| 2021 | $1.6M | 16,147 | 7,986 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.6M | 7,073 | 87.1% |
| Food and Beverage | $2.0M | 94,949 | 6.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 637 | 3.9% |
| Travel and Lodging | $225,826 | 672 | 0.8% |
| Consulting Fee | $186,381 | 79 | 0.6% |
| Honoraria | $113,120 | 39 | 0.4% |
| Education | $94,419 | 5,012 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $3,000 | 1 | 0.0% |
Payments by Type
Research
$25.6M
7,073 transactions
General
$3.8M
101,389 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY | Sumitomo Pharma America, Inc. | $7.0M | 1 |
| A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS | Sumitomo Pharma America, Inc. | $5.7M | 0 |
| SERENE | Sumitomo Pharma America, Inc. | $5.6M | 2 |
| A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy | Sumitomo Pharma America, Inc. | $2.1M | 3 |
| A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy | Myovant Sciences GmbH | $1.5M | 2 |
| Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis | Myovant Sciences GmbH | $1.3M | 2 |
| SPIRIT EXTENSION AN INTERNATIONAL PHASE 3 OPENLABEL, SINGLEARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX COADMINISTERED WITH LOWDOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSISASSOCIATED PAIN | Sumitomo Pharma America, Inc. | $1.0M | 0 |
| A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN HEALTHY WOMEN 18 TO 35 YEARS OF AGE WHO ARE AT RISK FOR PREGNANCY | Myovant Sciences GmbH | $410,840 | 0 |
| AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | Myovant Sciences Inc. | $211,652 | 0 |
| SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | Myovant Sciences Inc. | $198,462 | 0 |
| ADDRESSING DISPARATIES IN CARE IN BLACK WOMEN WITH UTERINE FIBROIDS | PFIZER INC. | $185,409 | 0 |
| SPIRIT EXTENSION AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | Myovant Sciences Inc. | $144,740 | 0 |
| THE EFFECT OF MEDICAL MANAGEMENT FOLLOWING EXCISIONAL SURGERY FOR ENDOMETRIOSIS A RANDOMIZED CONTROLLED TRIAL | PFIZER INC. | $139,369 | 0 |
| LIBERTY EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY TO EVALUATE RELUGOLIX CO-ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | Myovant Sciences Inc. | $81,483 | 0 |
| SPIRIT 1: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | Myovant Sciences Inc. | $30,568 | 0 |
| SPIRIT 2: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | Myovant Sciences Inc. | $22,249 | 0 |
| ADDRESSING DISPARITIES IN CARE IN BLACK WOMEN WITH UTERINE FIBROIDS | PFIZER INC. | $19,363 | 0 |
| AN INTERNATIONAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF RELUGOLIX WITH ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | Myovant Sciences Inc. | $16,248 | 0 |
| SPIRIT 1 AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | Myovant Sciences Inc. | $2,019 | 0 |
Top Doctors Receiving Payments for MYFEMBREE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| David Billings | — | Lumberton, NC | $25.5M | 7,056 |
| , M.D | Specialist | Tampa, FL | $154,000 | 287 |
| , MD | Obstetrics & Gynecology | Plantation, FL | $137,983 | 179 |
| , MD | Obstetrics & Gynecology | Mentor, OH | $89,779 | 124 |
| , MD | Gynecology | Chicago, IL | $86,322 | 95 |
| , MD | Gynecology | Phoenix, AZ | $82,456 | 21 |
| , MD, MPH | Gynecology | Peachtree Corners, GA | $78,805 | 133 |
| , M.D | Gynecology | Durham, NC | $70,214 | 64 |
| , M.D | Reproductive Endocrinology | Newport News, VA | $56,325 | 67 |
| , M.D | Reproductive Endocrinology | Washington, DC | $55,085 | 46 |
| , M.D | Obstetrics & Gynecology | Wellington, FL | $47,470 | 88 |
| , MD | Obstetrics & Gynecology | Corpus Christi, TX | $35,978 | 85 |
| , M.D | Gynecology | Shreveport, LA | $35,736 | 24 |
| Ayman Al-Hendy | Obstetrics & Gynecology | Chicago, IL | $35,514 | 21 |
| , M.D | Gynecologic Oncology | Scottsdale, AZ | $34,814 | 29 |
| , MD | Obstetrics & Gynecology | Little Rock, AR | $32,479 | 9 |
| , MD | Obstetrics & Gynecology | Chesapeake, VA | $32,043 | 53 |
| , MD | Gynecology | Charlotte, NC | $25,484 | 54 |
| , M.D | Obstetrics & Gynecology | Brockton, MA | $25,069 | 106 |
| , MD | Obstetrics & Gynecology | Fountain Valley, CA | $23,848 | 79 |
| , MD | Obstetrics & Gynecology | Winter Park, FL | $23,409 | 53 |
| , M.D | Obstetrics & Gynecology | Columbus, GA | $22,108 | 4 |
| , M.D | Specialist | West Haverstraw, NY | $18,534 | 7 |
| , M.D., PH.D | Reproductive Endocrinology | Bethesda, MD | $17,496 | 15 |
| , M.D | Obstetrics & Gynecology | Omaha, NE | $17,404 | 28 |
Ad
Manufacturing Companies
- Sumitomo Pharma America, Inc. $22.8M
- Myovant Sciences GmbH $3.2M
- Myovant Sciences Inc. $2.3M
- PFIZER INC. $1.1M
- Pfizer Inc. $21,366
- WHITEHALL INTERNATIONAL INC $16,000
Product Information
- Type Drug
- Total Payments $29.4M
- Total Doctors 20,490
- Transactions 108,462
About MYFEMBREE
MYFEMBREE is a drug associated with $29.4M in payments to 20,490 healthcare providers, recorded across 108,462 transactions in the CMS Open Payments database. The primary manufacturer is Sumitomo Pharma America, Inc..
Payment data is available from 2021 to 2024. In 2024, $12.8M was paid across 22,255 transactions to 8,117 doctors.
The most common payment nature for MYFEMBREE is "Unspecified" ($25.6M, 87.1% of total).
MYFEMBREE is associated with 19 research studies, including "A PHASE 3 SINGLEARM OPENLABEL STUDY TO EVALUATE THE SAFETY AND CONTRACEPTIVE EFFICACY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS WHO ARE 18 TO 50 YEARS OF AGE AND AT RISK FOR PREGNANCY" ($7.0M).